Accro Bioscience Grants Fosun Pharma Exclusive Rights for TYK2/JAK1 Inhibitor in Greater China

Accro Bioscience, a biotechnology company, has entered into an agreement granting Fosun Pharma exclusive rights to develop, manufacture, and commercialize its TYK2/JAK1 inhibitor, AC-201, in Greater China, encompassing Chinese Mainland, Hong Kong SAR, and Macau SAR. Accro will retain global rights for AC-201 outside these regions.

Under the terms of the deal, Accro will receive an upfront payment of RMB 60 million and a milestone payment of RMB 20 million upon completion of manufacturing technology transfer, totaling RMB 80 million. Additionally, Accro is eligible for up to RMB 76 million in development milestone payments, along with commercial milestone payments and tiered royalties reaching double-digit percentages based on sales in the licensed territories.

AC-201 is a novel oral small-molecule inhibitor targeting the pseudo kinase domain (JH2) of TYK2/JAK1, designed to minimize impact on the JAK2/JAK2 signaling pathway. The drug, intended for treating immune-mediated inflammatory diseases, has completed a Phase II clinical trial for moderate-to-severe plaque psoriasis. The trial results showed that all dose groups met the primary and key secondary endpoints after 12 weeks, with AC-201 demonstrating safety and tolerability, and no adverse events leading to discontinuation or serious adverse events reported.

Dr. Xiaohu Zhang, co-founder and CEO of Accro Bioscience, stated: “We are delighted to work with Fosun Pharma. Fosun’s extensive clinical development experience and commercialization capabilities will accelerate the development of AC-201 and enhance drug accessibility, bringing exceptional treatment options to patients with autoimmune diseases in the region as soon as possible.”

Xingli Wang, Co-President of Fosun Pharma and CEO of its Global R&D Center, said: “We are delighted to enter into this collaboration with Accro. AC-201, as a highly selective TYK2/JAK1 inhibitor, demonstrates significant clinical potential in the treatment of autoimmune diseases. Fosun Pharma remains committed to introducing and developing innovative therapies with breakthrough significance to address unmet medical needs. This partnership will further enrich our pipeline in the immunology and inflammation field.”